Jubilant Pharmova Ltd Q2FY26 – The ₹17,400-Crore Comeback Kid Mixing Science, Sterile Injectables & Some Desi Drama in Spokane
1. At a Glance
Welcome to the world of Jubilant Pharmova Ltd, where radiopharmaceuticals meet cardiac scans, allergy venoms meet government contracts, and sterile injectables meet sterile press releases. Market cap? ₹17,441 crore. Current price ₹1,096 — down 2% today because Mr. Market doesn’t appreciate cardiac imaging humor.
Quarterly sales for Q2FY26 came in at ₹1,966 crore, up 12.2% YoY, while PAT rose 9.8% to ₹124 crore. The operating margin? A cool 17%, a far cry from the COVID-era panic days when pharma firms printed money like Diwali sweets.
The company’s P/E of 35x may seem high — until you realize Sun Pharma trades at the same valuation for doing roughly 7x the sales. ROE sits at 9.55%, which in pharma terms translates to “healthy but not gym-rat ripped.” Debt-to-equity is 0.44x — manageable, unless you count the USD 570 million capex plan lurking in the corner like a gym subscription you keep forgetting to cancel.
Still, the balance sheet’s cleaner, the Spokane plant’s new high-speed isolator line is running, and the company just dumped its API business onto a subsidiary (Biosys) — the financial equivalent of cleaning your room by throwing everything into another cupboard.
2. Introduction
Once upon a molecule, Jubilant Pharmova was part of the all-encompassing Jubilant Life Sciences — the same house that brought you everything from chemicals to life-saving drugs. Then came the demerger in 2021, and the “Pharmova” name was born — probably after a three-hour Zoom brainstorm that ended with “Let’s just add a ‘va’.”
Fast forward to FY26, and this Noida-headquartered pharma player has found its rhythm — not in the crowded generics lane, but in radiopharma, contract manufacturing, and drug discovery.
The global pharma world may chase AI and mRNA, but Jubilant plays in high-entry-barrier niches: nuclear medicine, allergy extracts, sterile injectables, and clinical research. Think of it as the pharma equivalent of a college topper who skips college fests to ace the boring subjects.
The story now is of reinvention — new product launches, facility upgrades, FDA comeback stories, and divestments that sound fancy but basically say: “We’re tired of low-margin stuff, bro.”
3. Business Model – WTF Do They Even Do?
Good question, because Jubilant’s business model is a buffet of complex terms that could double as spellings in a pharma spelling bee. Here’s how it breaks down (9MFY24 revenue mix):
a) Radiopharma (~44%) – The company’s heart and soul (and radioactive isotope). #3 radiopharmaceutical manufacturer in the US with 46 radiopharmacies — only behind giants like Cardinal and GE. Their products like Mertiatide, Sulfur Colloid, and Ruby-Fill are used for imaging, especially for cardiac and cancer diagnostics. Ruby-Fill, in particular, is making waves in the US cardiac segment — because Americans love both burgers and cardiac scans.
b) Allergy Immunotherapy (~10%) – Jubilant’s Spokane unit manufactures venom extracts and allergy therapies. It’s the #2 player in the US allergenic extract market and the only supplier of venom extracts. Yes, literally selling snake venom for good health — you can’t make this up.
c) CDMO – Sterile Injectables (~17%) – The money-spinner. The Spokane and Montreal plants handle large-scale contract manufacturing of sterile injectables for clients, including the US government. A USD 132 million expansion launched Line-3 in Spokane this October — adding 50% capacity. Think of it as a new express lane for vaccines, vials, and vials of future revenue.
d) Generics (~12%) – The boring bit. Solid dosage formulations (Roorkee & Salisbury). The Maryland plant shut down in June 2024 after sustained losses — RIP Salisbury. Now, manufacturing will be outsourced via USFDA-approved partners.
e) CRDMO (~17%) – Contract Research, Development, and Manufacturing — their R&D engine. Operated via Biosys (Greater Noida, Bengaluru, and Nanjangud). This unit just absorbed the API business through a slump sale (Sept 2025). Think of this as the “lab coat division” that actually makes money from science, not marketing.
f) Proprietary Novel Drugs (~0.1%) – The moonshot. Oncology and autoimmune drug candidates like LSD1/HDAC6 inhibitor and JBI-778 (PRMT5 inhibitor) are in early stages. Basically, they’re testing futuristic molecules that might make headlines in 2030.
Six manufacturing facilities + two research centers = one globally awkward but strategically diversified portfolio.
Now, is it confusing? Of course. But profitable confusion is still profit.
4. Financials Overview
Source table
Metric
Q2FY26 (Latest)
Q2FY25 (YoY)
Q1FY26 (QoQ)
YoY %
QoQ %
Revenue
₹1,966 Cr
₹1,752 Cr
₹1,901 Cr
+12.2%
+3.4%
EBITDA
₹341 Cr
₹289 Cr
₹290 Cr
+18.0%
+17.6%
PAT
₹124 Cr
₹113 Cr
₹102 Cr
+9.8%
+21.6%
EPS (₹)
7.55
6.45
6.46
+17.0%
+17.0%
Commentary: Revenue rising, margins stable, PAT improving — finally some rhythm. OPM of 17% marks a recovery from
